Gerald J. Fetterly

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Monica Mita, Alain C. Mita, Quincy S. Chu et al. · Journal of Clinical Oncology · 2008 · 272 citations · Full text

Medicine, Oncology, Pharmacology +10

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand et al. · Clinical Cancer Research · 2017 · 172 citations

Medicine, Oncology, Pharmacokinetics +17

Pharmacokinetics of paclitaxel-containing liposomes in rats

Gerald J. Fetterly, Robert M. Straubinger · AAPS PharmSci · 2003 · 111 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)

Michael Smolinski, Yahao Bu, James L. Clements et al. · Journal of Medicinal Chemistry · 2018 · 99 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer

Emmanuel S. Antonarakis, Elisabeth I. Heath, Edwin M. Posadas et al. · Cancer Chemotherapy and Pharmacology · 2013 · 78 citations · Full text

Medicine, Oncology, Pharmacology +14